As Omi­cron-spe­cif­ic boost­ers are in the news, BioN­Tech to ex­pand Ger­man site work­force by 200 em­ploy­ees

4 years ago
Manufacturing

Roche nabs a pri­or­i­ty re­view for Evrys­di, hop­ing to be­come the first oral treat­ment for in­fants with SMA

4 years ago
Pharma
FDA+

A se­nior Bio­gen com­mer­cial ex­ec ex­its Alzheimer's unit amid ex­o­dus as Aduhelm woes mount

4 years ago
Pharma

No­var­tis mar­ket­ing vets move on to new com­mer­cial roles in biotech

4 years ago
People
Pharma

As Sanofi keeps shrink­ing its US HQ foot­print dur­ing pan­dem­ic, new own­ers scoop up its old cam­pus

4 years ago
Pharma

Celebri­ty cou­ple ac­tress Gabrielle Union and re­tired NBA star Dwyane Wade reprise roles in Mer­ck vac­ci­na­tion cam­paign

4 years ago
Pharma
Marketing

FDA+ roundup: Janet Wood­cock de­fends her 'most' will get Covid com­ment, talks short­ages and gov­ern­ment trust

4 years ago
FDA+

Biotech bears are maul­ing stocks as 2022 opens on a bleak note for in­vestors

4 years ago
Financing
Deals

Cor­texyme switch­es di­rec­tion, an­nounces lay­offs af­ter FDA slaps hold on dark horse Alzheimer’s can­di­date

4 years ago
FDA+

Cy­to­Dyn fires em­bat­tled CEO as its grow­ing cho­rus of crit­ics gets loud­er

4 years ago
People

Mi­cro­cap can­cer play­er goes bel­ly up af­ter pan­cre­at­ic tu­mor hope­ful flops key study

4 years ago
R&D

Dig­i­tal med com­pa­ny Ak­ili set to go pub­lic via Pal­i­hapi­tiya-backed SPAC — fur­ther­ing com­mer­cial launch and pipeline ...

4 years ago
Financing
R&D

Sanofi claims high-ris­es neigh­bor­ing its Toron­to fa­cil­i­ty would pose 'na­tion­al se­cu­ri­ty' threat

4 years ago
Pharma

FDA hur­ries up a quick ap­proval for the world's first TCR — af­ter a 14-year R&D trek

4 years ago
FDA+

Well-con­nect­ed, Gilead-backed biotech gets an­oth­er stack of cash to pur­sue CAR-Ts for au­toim­mune dis­ease

4 years ago
Financing
Cell/Gene Tx

Days af­ter Gilead yanks PI3K drug, In­cyte with­draws NDA for its own PI3K — say­ing con­fir­ma­to­ry tri­als would take ...

4 years ago
FDA+

In a set­back, FDA or­ders Gilead to hit the brakes on their late-stage, $5B can­cer play

4 years ago
R&D
FDA+

Opin­ion: Flori­da is so mAb crazy, Ron De­San­tis wants to use mAbs that don't work

4 years ago
R&D

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

4 years ago
In Focus
Marketing

Not cheap­er by the dozen: Bris­tol My­ers be­comes the 12th phar­ma com­pa­ny to re­strict 340B sales

4 years ago
Pharma

New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

4 years ago
Pharma

Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

4 years ago
Pharma
Marketing

Phar­ma reps need to bone up on sci­en­tif­ic da­ta and re­al-world ev­i­dence for on­col­o­gy dis­cus­sions: study

4 years ago
Pharma
Marketing

Am­gen’s #Dear­Asth­ma spon­sored tweet lands big on game day, spark­ing thou­sands to re­spond

4 years ago
Pharma
Marketing
First page Previous page 585586587588589590591 Next page Last page
A service from the Financial Times